Retraction of: Scientific Reports https://doi.org/10.1038/s41598-017-10325-x, published online 29 August 2017
The Editors have retracted this Article.
After publication of this Article, concerns were raised regarding some image irregularities and data concerns. Specifically:
-
Figure 4D, Vehicle, tunel antibody in this Article and Figure 4D, Vehicle, tunel antibody in1 appear to be highly similar;
-
Figure 4B appears to have signs of digital editing and there appear to be a discrepancy between the tumours in the image and the quantification of the tumour weights;
-
Supplementary Figure 3B, DMSO (HTH83) and Supplementary Figure 3B, 125 nM (HTH83) appear to be highly similar and to present signs of digital editing;
-
Supplementary Figure 3B, DMSO (CAL62) and Supplementary Figure 3B, 125 nM (CAL62) appear to be highly similar and to present signs of digital editing.
In addition, Figure 2C, Cal62 (0-63-125-250-500-1000) and Figure 2A, SW872 (0-125-250-500-1000-2000) in1 appear to be highly similar.
Upon request, the Authors were able to provide the raw data for Figure 2C but not for the other image concerns, and were not able to provide a satisfactory response to the concerns raised. The Editors no longer have confidence in the presented data.
Manoj Garg and Trivadi S Ganesan disagree with this retraction.
Deepika Kanojia, Anand Mayakonda, Bindhya Sadhanandhan, Sidhanth Suresh, Sneha S., Rohit P. Nagare, Jonathan W. Said, Ngan B. Doan, Ling-Wen Ding, Erkan Baloglu, Sharon Shacham, Michael Kauffman and H. Phillip Koeffler did not respond to correspondence from the Publisher about this retraction.
Reference
Garg, M. et al. Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget 8(5), 7521 (2016).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Garg, M., Kanojia, D., Mayakonda, A. et al. Retraction Note: Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Sci Rep 15, 43808 (2025). https://doi.org/10.1038/s41598-025-31415-1
Published:
Version of record:
DOI: https://doi.org/10.1038/s41598-025-31415-1
